Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747454 | 0.90 | POLB (0.48) | LMNAALDH1A1APPHSD11B1PKM | |
| SCHEMBL3757100 | 0.88 | HSD11B1 (0.52) | LMNAALDH1A1HSD11B1PKMNPC1 | |
| SCHEMBL3744663 | 0.77 | HSD11B1 (0.48) | LMNAALDH1A1HSD11B1CYP2D6CYP2C19 | |
| SCHEMBL3749431 | 0.74 | APP (0.45) | LMNAALDH1A1APPHSD11B1PKM | |
| SCHEMBL3742443 | 0.73 | KMT2A (0.43) | LMNAALDH1A1PKMRAB9ACYP2C19 | |
| SCHEMBL3752153 | 0.72 | POLB (0.50) | LMNAALDH1A1APPHSD11B1PKM | |
| SCHEMBL3742454 | 0.68 | HSD11B1 (0.44) | LMNAALDH1A1HSD11B1PKM | |
| SCHEMBL7510989 | 0.67 | KMT2A (0.82) | LMNAALDH1A1PKM | |
| SCHEMBL3749402 | 0.67 | CYP2D6 (0.43) | ALDH1A1HSD11B1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3744641 | 0.66 | HSD11B1 (0.47) | LMNAALDH1A1HSD11B1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | LMNA 4192/4885ALDH1A1 2555/4885APP 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.